H.C.
RBC Capital’s Douglas Miehm anticipates Wall Street could be discounting a first quarter guidance lift considering latest VRX share price performance.
Deutsche Bank’s Gregg Gilbert now angles for 22% in return potential for VRX shares following good litigation news for largest drug Xifaxan.
Ortho Dermatologics, a division of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced that the Journal of the American Academy of Dermatology (JAAD) published for the first …
Mizuho’s Irina Rivkind Koffler has gotten more upbeat on the VRX name, but her raised expectations watch for 6% in loss potential for the stock.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary Salix is fostering a new two-way conversation between health care providers and irritable bowel syndrome …
Canaccord’s Neil Maruoka jumps up his price target on VRX, but even with more optimism, still angles for 5% downside potential from the stock.
Salix Pharmaceuticals, a wholly owned subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced today that the U.S.
Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.
Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.
